<DOC>
	<DOCNO>NCT00760916</DOCNO>
	<brief_summary>This study international , multi-center , randomize , double-blind , placebo-controlled study subject PAH currently receive approve therapy PAH ( i.e. , endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor ) monotherapy treatment . Study visit occur 4 week interval 12 week key measure efficacy 6-minute walk test . Study procedure include routine blood test , medical history , physical exam , disease evaluation , exercise test . At end first 12-weeks , patient un-blinded . Patients continue another 12-Week open label portion visit occur 4-week interval . Patients complete assessment 24-weeks also eligible enter 36 month open-label , extension phase study ( FREEDOM - EXT ) .</brief_summary>
	<brief_title>FREEDOM DR : Oral Treprostinil Combination With Endothelin Receptor Antagonist ( ERA ) and/or Phosphodiesterase-5 ( PDE-5 ) Inhibitor Monotherapy Treatment Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description>This study international , multi-center , randomize , double-blind , placebo-controlled study subject PAH currently receive approve therapy PAH ( i.e. , endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor ) monotherapy treatment . Study visit occur 4 week interval 12 week key measure efficacy 6-minute walk test . Study procedure include routine blood test , medical history , physical exam , disease evaluation , exercise test . At end first 12-weeks , patient un-blinded . Patients continue another 12-Week open label portion visit occur 4-week interval . Patients complete assessment 24-weeks also eligible enter 36 month open-label , extension phase study ( FREEDOM - EXT ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Between 18 70 year age , inclusive Body weight least 50 kilogram PAH either idiopathic/familial ; associate repair congenital systemictopulmonary shunt ( repair â‰¥ 5 year ) ; associate collagen vascular disease ; associate HIV . Currently receive approve endothelin receptor antagonist and/or approve phosphodiesterase5 inhibitor least 90 day stable dose least last 30 day currently receive approve PAH therapy . Previous test ( e.g. , right heart catheterization , echocardiography ) consistent diagnosis PAH . Reliable cooperative protocol requirement . Nursing pregnant . Received prostacyclin within past 30 day . PAH due condition note inclusion criterion . History uncontrolled sleep apnea , renal insufficiency , anemia , leave sided heart disease , uncontrolled systemic hypertension , parenchymal lung disease . Use investigational drug within 30 day Baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
</DOC>